Great Point Partners LLC Decreases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Great Point Partners LLC reduced its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 40.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 959,953 shares of the company’s stock after selling 641,574 shares during the period. Voyager Therapeutics comprises 1.7% of Great Point Partners LLC’s investment portfolio, making the stock its 21st largest position. Great Point Partners LLC’s holdings in Voyager Therapeutics were worth $5,616,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Plato Investment Management Ltd purchased a new position in shares of Voyager Therapeutics during the first quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $74,000. SG Americas Securities LLC bought a new stake in shares of Voyager Therapeutics during the second quarter valued at approximately $85,000. Finally, ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics during the first quarter valued at approximately $101,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Down 1.4 %

Shares of NASDAQ VYGR opened at $5.67 on Wednesday. Voyager Therapeutics, Inc. has a twelve month low of $5.19 and a twelve month high of $11.72. The firm has a market cap of $309.75 million, a P/E ratio of 7.99 and a beta of 0.89. The company has a 50 day moving average of $6.53 and a 200 day moving average of $7.36.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same period in the previous year, the business earned ($0.59) EPS. As a group, equities analysts expect that Voyager Therapeutics, Inc. will post -1.03 earnings per share for the current fiscal year.

Insider Activity

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.53% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Wedbush lowered their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $17.00.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.